Zealand Pharma to participate in upcoming investor conferences
Zealand Pharma (Nasdaq: ZEAL) announced participation in upcoming investor conferences in April 2021. The company's senior management will present at the Guggenheim Virtual Healthcare Talks on April 1, and at the 20th Annual Virtual Needham Healthcare Conference on April 12, with a presentation scheduled at 11:45 a.m. ET. Live webcasts will be available on the company's website, with replays archived post-event. Zealand focuses on innovative peptide-based medicines for metabolic and gastrointestinal diseases.
- None.
- None.
Company announcement – No. 17 / 2020
Zealand Pharma to participate in upcoming investor conferences
Copenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in April:
| Guggenheim Virtual Healthcare Talks - Genomic Medicines & Rare Disease |
| Date: Thursday, April 1, 2021 |
| 20th Annual Virtual Needham Healthcare Conference |
| Date: Monday, April 12, 2021 |
| Presentation: 11:45 a.m. ET/ 4:45 p.m. CET |
A live webcast of the Needham event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
For further information, please contact:
Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
FAQ
What investor conferences is Zealand Pharma participating in April 2021?
When is Zealand Pharma's presentation at the Needham Healthcare Conference?
Where can I find the live webcast of Zealand Pharma's presentations?
What is Zealand Pharma's focus as a biotechnology company?
What stock symbol is associated with Zealand Pharma?
